Neon drop · Free ship $75+ · Enter the grid
Signal · Product Feed

NVP-BEP800 Catalog No.:M7899-2 Hit-to-lead studies: The discovery of

SKU: 61222495141

4.7
DKK120.00 DKK146.00

Pay in 4 interest-free payments of $30.00 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 6 - Aug 11

Live Spec

NVP-BEP800 Catalog No.:M7899-2 Hit-to-lead studies: The discovery ofNVP BEP800, also known as BEP 800, is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2) terminal ATP binding pocket of Hsp90. NVP BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concentrations. In A375 melanoma and BT 474 breast cancer cell lines, NVP BEP800 induced client protein degradation (including ErbB2, B Raf(V600E), Raf 1, and Akt) and Hsp70

Store: juliusking.com · Domain: juliusking.com

Description

Hit-to-lead studies: The discovery of potent

and combination therapy resulted in the greatest tumor weight reduction

2007 Oct 28

1-dioxo-3-[(pyridin-2-yl)carbamoyl]-2H-1

CAS Number: 331771-20-1

NVP-BEP800 Catalog No.:M7899-2 Hit-to-lead studies: The discovery ofNVP BEP800, also known as BEP 800, is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2) terminal ATP binding pocket of Hsp90. NVP BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concentrations. In A375 melanoma and BT 474 breast cancer cell lines, NVP BEP800 induced client protein degradation (including ErbB2, B Raf(V600E), Raf 1, and Akt) and Hsp70

Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products